Flying The Web For News.
  • Career Exam Study
    Career Exam Study
  • 2024 Presidential Election
    2024 Presidential Election
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News

Article Tools/Herramientas de artículos

+ Larger Font/Fuente más grande | - Smaller Font/Fuente más pequeña



Globe NewsWire News Distribution Service

Press Release: Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Details
Category: Globe NewsWire News Distribution Service

Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028 Study 1 of Essential3 program for ulixacaltamide in essential tremor (ET) on track for Q1 2025 interim analysis; NDA filing for ulixacaltamide expected in 2025


Posted: 2025-01-13 02:00:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

Tags

press | release | praxis | precision | medicines


Related News Stories From The Web And More

Related Bing News Search Results

Press Release: Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities - Newscast

Praxis Precision Medicines (NASDAQ: PRAX)

Fri, 31 Jan 2025 08:00:00 GMT Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS ...

Truist raises Praxis stock target to $175 on study optimism

Tue, 21 Jan 2025 10:21:11 GMT Praxis Precision Medicines Inc . (NASDAQ:PRAX) shares received a boost as Truist Securities increased its price target for the company to $175 from $150, while maintaining a Buy rating. The stock, ...

Expert Outlook: Praxis Precision Medicine Through The Eyes Of 5 Analysts

Tue, 21 Jan 2025 07:00:00 GMT Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Praxis Precision Medicine PRAX in the last three months. The table below provides a snapshot ...

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Sun, 12 Jan 2025 19:00:00 GMT Sodium channel therapy is the cornerstone of treatment for patients with epilepsy yet currently approved drugs ... this press release speaks only as of the date on which it is made. Praxis ...

Praxis Precision Medicines Highlights Late-Stage Clinical Trial Advancements and 2025 Milestones

Sun, 12 Jan 2025 18:10:00 GMT Praxis Precision Medicines ... the predominant genetic link to de novo autism spectrum disorders (ASD). This press release contains forward-looking statements within the meaning of The Private ...


Blow Us A Whistle